

Curriculum Vitae

Personal information

Name **Federica De Galitiis**

Professional address **Istituto Dermatologico dell'Immacolata IDI-IRCCS**
Via Monti di Creta, 104 - 00167 Rome (Italy)

Phone

E-mail f.degalitiis@idi.it

Date of birth

Nationality Italian

Profession **Medical Oncologist**

Work experience

March 2018 - present: **Medical Director and Chief** of the UOC Oncology, IDI-IRCCS, Rome

2017 - present: Registration to the Order of Experts and Collaborators of **Agenas** in the Clinical / Organizational / Epidemiological / Social Area

Nov 2016: **Professor at the II Level Master of Immuno-oncology** at the La Sapienza University, Rome

Dec 2012 - Oct 2013: **Medical Director** at the Oncology Department, ASL of Teramo, Giulianova and Sant'Omero hospital

Sept 2011: **Scientific consultant for Bristol-Myers Squibb S.r.l.** with participation at the training on Melanoma for Medical Scientific Representatives

2009 - April 2015: **Consultant** at the General Surgery Department, San Carlo di Nancy hospital, Rome

Aug 2006 - present: Full time **Medical Director** at the UOC Oncology, IDI-IRCCS, Rome

July 2005 - March 2006: **Medical Director** at the Oncology Department, ASL of Teramo, Giulianova and Sant'Omero hospital

Dec 2003 - Dec 2005: **Medical assistance activities** as On-Call Doctor and as Substitute for General Practitioners at the Sanatrix Affiliated Clinic, L'Aquila

Jan 2003 - June 2005: **Medical assistance activities** at the CUS L'Aquila Rugby Society and at the Italian Federation of the Regional Rugby Committee

2002 - 2003: **Technical / scientific collaboration contract** at the Department of Experimental Medicine, University of L'Aquila

	<p>Education</p> <p>March 2021: First training ICH-GOOD CLINICAL PRACTICE (GCP)</p> <p>April 2019: Training course "Campus in Oncology", Capri (NA)</p> <p>June 2015: II Level Master in Management of Health Services (MAS), LUISS</p> <p>April 2006: PhD in Experimental Medicine and Endocrinology, "Genetic alterations of clinical relevance in sporadic and hereditary colorectal cancer"</p> <p>1998 - 2002: Post-graduate Specialization in Oncology, University of L'Aquila, "Determination of p53 gene mutations by FAMA in colorectal neoplasms. Prognostic evaluations"</p> <p>1998 Degree in Medicine and Surgery, 108/110, University of L'Aquila, "Molecular Mechanism of Action of Mitoxantrone in Solid Neoplasms"</p> <p>1988 Classical High School diploma at the Liceo Classico, Luigi Illuminati, Atri (TE)</p>
<p>Mother tongue</p>	<p>Italian</p>
<p>Other languages</p>	<p>English and French</p>
<p>Further information</p>	<p>Participation in National Research Projects (MIUR):</p> <ul style="list-style-type: none"> - 2001: Family cancer of the breast and ovary. Multicenter study on biological and clinical characteristics and on the management of subjects at risk - Development of diagnostic-molecular strategies for the recognition of structural inactivation of the BRCA1 and BRCA2 genes and of chemoprevention programs in women with a genetic predisposition to breast cancer - 2003: Hereditary tumors of the breast: genetic studies and proteome analysis - Identification and clinical management of families with BRCA1 / BRCA2 genetic predisposition and molecular characterization of proliferative pathologies in carriers - 2004: Biomolecular characterization of breast carcinoma for the development of innovative systemic primary therapies - Characterization of the p53 genotype and gene expression profiles in breast cancer for the development of individual systemic primary therapies

Scientific publications

- Identification of immunological patterns characterizing immune-related psoriasis reactions in oncological patients in therapy with anti-PD-1 checkpoint inhibitors
Morelli M, et al. *Frontiers in Immunology*. 2024 Mar 01;15:1346687
- Primary Mucosal Melanoma: Clinical Experience from a Single Italian Center
Falcone R, et al. *Curr Oncol*. 2024 Jan 22;31(1):588-597
- The Impact of Drug-Drug Interactions on the Toxicity Profile of Combined Treatment with BRAF and MEK Inhibitors in Patients with BRAF-Mutated Metastatic Melanoma
Mezi S, et al. *Cancers (Basel)*. 2023 Sep 15;15(18):4587
- Italian nivolumab Expanded Access Program in melanoma adjuvant setting: patient outcomes and safety profile
Ascierto PA, et al. *Eur J Cancer*. 2023 Sep;191:113246
- Pituitary Enlargement and Hypopituitarism in Patients Treated with Immune Checkpoint Inhibitors: Two Sides of the Same Coin?
Chiloiro S, et al. *J Pers Med*. 2023 Feb 26;13(3):415
- Cross-Cultural Adaptation and Preliminary Validation of Upper Limb Lymphedema Quality of Life Questionnaire (ULL-27) in Italian Female Patients with Breast Cancer-Related Lymphedema
Samela T, et al. *Lymphat Res Biol*. 2022 Dec;20(6):651-658
- KEYNOTE-716 Investigators. Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial.
Long GV, et al. *Lancet Oncol*. 2022 Nov;23(11):1378-1388
- Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study.
Khattak MA, et al. *Eur J Cancer*. 2022 Nov;176:207-217
- Vitiligo-like leukoderma as an indicator of clinical response to immune checkpoint inhibitors in late-stage melanoma patients
Verkhovskaia S, et al. *J Cancer Res Clin Oncol*. 2022 Sep;148(9):2529-2538
- Circulating miR-1246 and miR-485-3p as Promising Biomarkers of Clinical Response and Outcome in Melanoma Patients Treated with Targeted Therapy
Levati L, et al. *Cancers (Basel)*. 2022 Jul 29;14(15):3706
- Corrigendum to "Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma"
Baggi A, et al. *Eur J Cancer*. 2022 May;166:309-310
- KEYNOTE-716 Investigators. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial.
Luke JJ, et al. *Lancet*. 2022 Apr 30;399(10336):1718-1729
- Vitiligo-specific soluble biomarkers as early indicators of response to immune checkpoint inhibitors in metastatic melanoma patients.
Carbone ML, et al. *Sci Rep*. 2022 Mar 31;12(1):5448
- Clinical Predictors of Response to Anti-PD-1 First-Line Treatment in a Single-Centre Patient Cohort: A Real-World Study.
Di Pietro FR, et al. *Clin Oncol*. 2022 Jan;34(1):e18-e24

Clinicians' Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, "Real-Life", Case-Control Study.

Parisi A, et al. Clin Colorectal Cancer. 2021 Dec;20(4):318-325

Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma.

Baggi A, et al. Eur J Cancer. 2021 Nov;157:250-258

Vitiligo-like leukoderma as an indicator of clinical response to immune checkpoint inhibitors in late-stage melanoma patients.

Verkhovskaia S, et al. J Cancer Res Clin Oncol. 2021 Sep. doi: 10.1007/s00432-021-03811-3. Epub ahead of print.

The role of opioids in cancer response to immunotherapy.

Botticelli A, et al. J Transl Med. 2021 Mar 23;19(1):119

The integrated care pathway for non melanoma skin cancer: the Istituto Dermatologico dell'Immacolata - IRCCS experience in Rome.

Fania L, et al. Recenti Prog Med. 2020 Dec;111(12):749-760

Reduction of T Lymphoma Cells and Immunological Invigoration in a Patient Concurrently Affected by Melanoma and Sezary Syndrome Treated With Nivolumab.

Narducci MG, et al. Front Immunol. 2020 Sep 25;11:579894

Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study.

Nigro O, et al. Eur J Cancer. 2020 Jul;134:19-28

The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with Immunotherapy.

Botticelli A, et al. Vaccines (Basel). 2020 Apr 28;8(2):203

Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events

Cortellini A, et al. Eur J Cancer. 2020 Mar;128:17-26

Evaluating the role of Family history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study.

Cortellini A, et al. Oncoimmunology. 2020 Jan 7;9(1):1710389

Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice.

Cortellini A, et al. J Transl Med. 2019 Nov 15;17(1):376

Insulin Resistance as a Risk Factor for Cutaneous Melanoma. A Case Control Study and Risk-Assessment Nomograms.

Scoppola A, et al. Front Endocrinol (Lausanne). 2019 Nov 5;10:757

A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable.

Cortellini A, et al. J Immunother Cancer. 2019 Feb 27;7(1):57

Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study.

Cortellini A, et al. Oncologist. 2019 Feb 22

Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study.
Pistillo MP, et al. *Cancer Immunol Immunother.* 2019 Jan;68(1):97-107

CTLA-4 gene variant -1661A>G may predict the onset of endocrine adverse events in metastatic melanoma patients treated with ipilimumab.
Queirolo P, et al. *Eur J Cancer.* 2018 Jul;97:59-61

Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study.
Queirolo P, et al. *Front Immunol.* 2017 Apr 12;8:386

Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients.
Ferrucci PF, et al. *Br J Cancer.* 2015 Jun 9;112(12):1904-10

Appropriatezza e costi del follow-up nelle pazienti con carcinoma della mammella.
De Galitiis F. *Mondo Sanitario*, 2016

Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access program in Italy.
Chiarion-Sileni V, et al. *Br J Cancer.* 2014 Apr 1;110(7):1721-6

Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma.
Del Vecchio M, et al. *Eur J Cancer.* 2014 Jan;50(1):121-7

Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma.
Maio M, et al. *Ann Oncol.* 2013 Nov;24(11):2911-5

"Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (Flr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study.
Bruera G, et al. *BMC Cancer.* 2010 Oct 19;10:567

Triplet schedule of weekly 5-fluorouracil and alternating irinotecan or oxaliplatin in advanced colorectal cancer: a dose-finding and phase II study.
Morelli MF, et al. *Oncol Rep.* 2010 Jun;23(6):1635-40.

Novel P53 mutations detected by FAMA in colorectal cancers
De Galitiis F, et al. *Ann Oncol.* 2006 Jun;17 Suppl 7:vii78-vii83

Increased tolerability of bimonthly 12-hour timed flat infusion 5-fluorouracil/irinotecan regimen in advanced colorectal cancer: A dose-finding study.
Ficarella C, et al. *Oncol Rep.* 2006 May;15(5):1345-50

Timed flat infusion of 5-Fluorouracil increases the tolerability of 5-fluorouracil/docetaxel regimen in metastatic breast cancer: a dose finding study
Ficarella C, et al. *Br J Cancer.* 2004 Aug 16;91(4):618-20

Can analysis of the molecular status of the p53 gene contribute to improving the therapeutic strategy for breast carcinoma?
Ricevuto E, et al. *Ficarella Tumori.* 2003 Jul-Aug;89(4 Suppl):197-9

Prognostic value of p53 molecular status in high-risk primary breast cancer
Marchetti P, et al. *Annals of Oncology* 2003 May; Vol 14: 704-708

P16 hypermethylation contributes to the characterization of gene inactivation profiles in primary gastric cancer
C Ficarella, et al. *Oncology Reports* 2003 Jan-Feb; Vol.10(1):169-73

Familiarity and heredity of tumors in function of an early surgical therapeutic approach
Ricevuto E, et al. Suppl Tumori. 2002 May-Jun;1(3):S89-91

Significato prognostico e predittivo delle alterazioni genetiche nel carcinoma gastrico
Ficarella C, et al. Minerva Medica, 1991, Suppl. 1, N1/2: 48-50, 2000

Terapia adiuvante nel carcinoma del colon retto in età geriatrica
Ficarella C, et al. Minerva Medica, 1990: 232-3; 19

Congresses and Courses as Speaker or Professor

28/02/2023 Editorial board member "SETTING NEXT HORIZON", Rome

25/11/2022 Speaker at the meeting "Aiom: Best of the year 2022", Rome

09/12/2019 Professor at the meeting "Difficult cases in immuno-oncology", Rome

05/04/2019 Professor at the course "NIVOLUTION – Live around", Rome

23/11/2018 Speaker at the Course "PROMETEO - project melanoma immunological therapy",
Rome

04/11/2018 Speaker at the "XXIV national congress IMI", Bari

18/05/2018 Speaker at the meeting "NEXT 2018-WHO pNEN project and in clinical cases",
Rome

07/07/2016 Professor at the course "Melanoma Life / Live", Rome

30/09/2016 Speaker at the Course "Immuno-Oncology in the treatment of cancer: Innovation,
Access and Sustainability", Rome

02/24/2016 Speaker at the Conference: Oligometastatic disease. Past, Present and Future,
Rome

19/06/2014 Speaker at the Seminar of Immuno.-Oncology: the new frontier of cancer therapy,
Bari

12/06/2014 Speaker at the Course "MAME: Management of Metastatic Melanoma"

11/05/2012 Speaker at the Conference "Metastatic Breast cancer", Bologna

29/06/2006 Speaker at the Course "The treatment of hormone-sensitive breast cancer: a
changing scenario"

06/2006 Speaker at the VIII GOIM Conference "From Biomolecular and Technological
Innovations to Clinical Application", Messina

*I authorize the treatment of personal data contained in my CV according to the current
Italian directives (art.13 of D. Lgs. 196/2003 and art.13 GDPR 679/16)*